Vivo Capital LLC Has $7.13 Million Position in Rezolute, Inc. (NASDAQ:RZLT)

Vivo Capital LLC trimmed its position in Rezolute, Inc. (NASDAQ:RZLT - Free Report) by 13.7% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,797,704 shares of the company's stock after selling 445,138 shares during the quarter. Vivo Capital LLC owned 6.97% of Rezolute worth $7,134,000 at the end of the most recent reporting period.

Separately, Federated Hermes Inc. raised its position in shares of Rezolute by 53.6% in the fourth quarter. Federated Hermes Inc. now owns 10,154,327 shares of the company's stock valued at $10,083,000 after buying an additional 3,544,053 shares in the last quarter. Hedge funds and other institutional investors own 82.97% of the company's stock.

Rezolute Trading Up 2.3 %

NASDAQ RZLT traded up $0.06 during trading on Friday, hitting $2.66. 203,470 shares of the company's stock were exchanged, compared to its average volume of 311,495. The stock's 50 day moving average price is $2.22 and its two-hundred day moving average price is $1.40. Rezolute, Inc. has a fifty-two week low of $0.72 and a fifty-two week high of $3.69. The company has a market cap of $106.75 million, a PE ratio of -2.42 and a beta of 1.29.

Rezolute (NASDAQ:RZLT - Get Free Report) last issued its quarterly earnings data on Tuesday, February 13th. The company reported ($0.27) EPS for the quarter, meeting the consensus estimate of ($0.27). Analysts forecast that Rezolute, Inc. will post -1.12 earnings per share for the current fiscal year.

Insider Activity

In other news, CFO Daron Evans acquired 41,900 shares of Rezolute stock in a transaction that occurred on Friday, February 16th. The shares were acquired at an average price of $1.30 per share, for a total transaction of $54,470.00. Following the transaction, the chief financial officer now directly owns 70,900 shares of the company's stock, valued at approximately $92,170. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, Director Young-Jin Kim acquired 36,503 shares of the stock in a transaction dated Thursday, March 7th. The stock was bought at an average cost of $1.91 per share, for a total transaction of $69,720.73. Following the completion of the transaction, the director now directly owns 115,450 shares of the company's stock, valued at $220,509.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Daron Evans acquired 41,900 shares of the business's stock in a transaction that occurred on Friday, February 16th. The stock was bought at an average cost of $1.30 per share, for a total transaction of $54,470.00. Following the completion of the purchase, the chief financial officer now owns 70,900 shares of the company's stock, valued at $92,170. The disclosure for this purchase can be found here. In the last ninety days, insiders bought 179,403 shares of company stock worth $306,601. Insiders own 18.20% of the company's stock.

Analyst Ratings Changes

RZLT has been the topic of a number of analyst reports. HC Wainwright reissued a "buy" rating and set a $14.00 price target on shares of Rezolute in a research report on Thursday, March 7th. Jonestrading started coverage on Rezolute in a research report on Thursday, April 18th. They issued a "buy" rating and a $10.00 price target on the stock. Maxim Group began coverage on shares of Rezolute in a research report on Tuesday, April 9th. They set a "buy" rating and a $8.00 price objective for the company. Finally, JMP Securities reissued a "market outperform" rating and issued a $7.00 target price on shares of Rezolute in a report on Thursday, April 18th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Rezolute currently has a consensus rating of "Buy" and an average price target of $8.80.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.

Want to see what other hedge funds are holding RZLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Rezolute, Inc. (NASDAQ:RZLT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.